Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002
Business Overview: The company provides innovative tools for drug discovery research, focusing on target validation, assay development, and ADMET screening. It operates globally with manufacturing and sales in the U.S., U.K., and Germany.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Total Revenues | $11,963 | $8,607 |
| Net Income | $773 | $272 |
| Operating Income | $1,182 | $518 |
| Cash from Operations | $346 | $1,569 |
| Cash and Equivalents (End of Period) | $30,039 | $42,388 |
| Total Debt (Current + Long-term) | $4,422 | N/A |
| EPS (Basic & Diluted) | $0.03 | $0.01 |
Note: Debt figures derived from Balance Sheet current installments ($3,882) and long-term debt ($540).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 39% to $11.96 million, driven by new product lines (spectrophotometers, plate readers) and growth from 2001 acquisitions. Foreign currency translation reduced reported revenue growth; at 2001 rates, growth would have been 41%.
- Profitability: Net income nearly tripled to $773,000. Operating income increased 128% to $1.18 million.
- Expense Trends:
- Cost of Product Revenue: Increased 32% to $5.75 million; margin improved 1.3% due to favorable product mix and direct sales.
- Sales & Marketing: Increased 66% to $1.49 million, primarily due to acquisitions and new personnel.
- R&D: Increased 136% to $1.02 million, largely due to the Union Biometrica acquisition.
- Stock Compensation: Decreased 57% to $325,000 from $761,000.
- Cash Flow: Operating cash flow decreased significantly to $346,000 from $1.57 million, primarily due to a $931,000 increase in accounts receivable.
- Accounting Changes: Adoption of SFAS No. 142 eliminated goodwill amortization starting Jan 1, 2002. Adjusted net income for Q1 2001 would have been $406,000 if comparable.
Guidance, Risks, and Contingencies
- Outlook: Management expects cash from operations and existing resources to be sufficient for the foreseeable future. However, future capital needs for product development or acquisitions may require additional financing, potentially diluting shareholders.
- Legal Proceedings:
- Harvard University: Lawsuit alleging trademark infringement regarding "Harvard Bioscience" and "Harvard Apparatus" names. Court denied preliminary injunction but restricted use of crimson color/font. Partial summary judgment issued against Harvard University regarding "Harvard Apparatus" name in May 2002.
- Paul D. Grindle: Arbitration initiated by former owner of Harvard Apparatus seeking return of ~1.56 million shares or $15 million in damages related to 1996 purchase price adjustments. Company intends to defend vigorously.
- Market Risks: Significant exposure to foreign currency exchange rates (U.K. and Germany operations). No hedging currently in place; risk managed via asset/liability matching.
- Intangible Assets: Initial impairment review for goodwill required under SFAS 142 expected in Q2 2002.
Investor Verification Checklist
- Accounts Receivable: Verify the $931,000 increase in receivables and its impact on future cash collections.
- Legal Exposure: Monitor the status of the Harvard University trademark litigation and the Grindle arbitration ($15M claim).
- Goodwill Impairment: Watch for the Q2 2002 goodwill impairment test results under SFAS 142.
- Acquisition Integration: Assess the performance of 2001 acquisitions (Union Biometrica) which drove significant R&D and S&M expense increases.
- Foreign Currency: Evaluate the impact of exchange rate fluctuations on future margins given the lack of hedging.